IVERIC bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating Activities
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation
Amortization of debt issuance costs
Amortization of premium and discounts on investment securities
Non-cash charge on acquired in-process research and development
Gain on sale of property and equipment
Non-cash gain on extinguishment of royalty purchase agreement
Deferred income taxes
Proceeds from sale of IC100 & IC 200
Share-based compensation
Change in working capital
Stock-based consideration in connection with license acquisition
Changes in operating assets and liabilities:
Income tax receivable
Due from Novartis Pharma AG
Other assets
Prepaid expense and other assets
Accrued interest receivable
Accrued research and development expenses
Accounts payable and accrued expenses
Deferred revenue

Net cash used in operating activities
Investing Activities
Purchase of marketable securities
Maturities of marketable securities
Purchase of property and equipment
Proceeds from sale of assets
Net cash provided by (used in) investing activities
Financing Activities
Proceeds from issuance of common stock
Inception 4
Public Stock Offering
Private Placement
Total proceeds from issuance of common stock

Proceeds from employee stock plan purchases and stock option exercises
Proceeds from term loan
Payment of term loan issuance costs
Net cash provided by financing activities
Net change in cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents
Beginning of period
End of period
Supplemental disclosure of cash paid
Interest expense paid in cash
Income taxes received, net
Supplemental disclosures of non-cash information related to investing activities
Change in unrealized gain (loss) on available for sale securities, net of tax
Common stock issued to acquire net assets of Inception 4, Inc.
Operating right-of-use assets obtained in exchange for lease obligations
Preferred stock received for the sale of IC100 & IC200

Comments